期刊文献+

抗P-选择蛋白人源性单克隆抗体的制备 被引量:2

The Preparation of Human Anti-P-Selectin Monoclonal Antibodies
下载PDF
导出
摘要 目的:获得人源性抗P-选择蛋白(selectin)特异性抗体,为相关疾病治疗奠定基础。方法:在HEK293细胞中真核分泌表达人P-选择蛋白功能性片段,以此蛋白片段作为抗原,利用本室构建的大容量全合成人源性噬菌体抗体库进行筛选,经过3轮固相筛选后,阳性克隆得到富集;将其中富集效果最好的一株单链抗体A1改造成全抗体(IgG1),重组质粒转染H293细胞后,抗体得到表达;表达后在全抗体水平上用ELISA和Western印迹分别验证了A1抗体的特异性,并通过非竞争ELISA方法初步测定这株抗体的亲和力。结果:3轮筛选得到3株特异性噬菌体抗体,其中富集效果最好的单链抗体A1改造成全抗体形式后特异性良好,抗体亲和力Kd=2×10-8 mol/L。结论:筛选得到一株特异性较好的抗P-选择蛋白人源性单克隆抗体A1,其特异性和亲和力较好,有继续开发的价值。 Objective: To obtain anti-human P-selectin monoclonal antibodies,and lay a basis for the therapy of P-selectin related diseases.Methods: P-selectin functional segment was expressed secretly by HEK293 cells,which was used as antigen for antibody panning.And then screening from the large fully synthetic human antibody library constructed in our lab,several candidates of antibodies specially binding to P-selectin were obtained,after 3 rounds of solid panning,the positive clones were enriched.Next,one candidates A1,which was enriched suffi-ciently,was transferred from scFv to whole antibody(IgG1).At last,using ELISA and Western blot to identify the specificity of A1.Also using non-competitive ELISA method to detecte the affinity of A1.Results: After panning,we got 3 different candidates,and changed one of them into whole antibody form.The ELISA and Western blot results showed that the specificity of A1 was excellent.Furthermore,the affinity of A1 was detected by non-com-petitive ELISA method and the affinity constant Kd was 2×10-8 mol / L.Conclusion: We got an excellent anti-hu-man Pselectin antibody candidant,which proved to have well specificity and affinity,so it has potential value to go on study.
出处 《生物技术通讯》 CAS 2010年第6期827-833,共7页 Letters in Biotechnology
基金 国家自然科学基金(30872401)
关键词 P-选择蛋白 真核表达 噬菌体抗体 筛选 特异性 亲和力 P-selectin eukaryotic expression phage displayed antibody specificity affinity
  • 相关文献

参考文献26

  • 1Bcwilacqua M P,Stengehn S,Gimbrone M A,et al.Endothelial leukocyte adhesion molecule:an inducible receptor for neatrophils related to complement regulatory proteras and lectins[J].Science,1989,243(3):1160-1165.
  • 2Siegelrnan M H,Van de Rijn M,Weiasnwn IL.Mouse lymphnode homing receptor cDNA clone encodes a glycoprotein revealing tandem interaction domains[J].Science,1989,243(4895):1165-1172.
  • 3Mcever R P.Selectin-carbohydrate interactions during intlamination and metastasis[J].Glycoconj J,1997,14(5):585-591.
  • 4Lindner V,Fingerle J,Reidy M A.Mouse model of arterial injury[J].Circ Res,1993,73:792-796.
  • 5Kraling B M,Razon M J,Boon L M,et al.E-selectin is present in proliferating endothelial cells in human hemangiomas[J].Am J Pathol,1996,148:1181-1191.
  • 6Zwaginga J J,Torres H I,Lammers J,et al.Minimal platelet deposition and activation in models of injured vessel wall optimal neutrophil adhesion under flow conditions[J].Arterioscler Thromb Vasc Biol,1999,19:1549-1554.
  • 7Simon S I,Goldsmith H L.Leukocyte adhesion dynamics in shear flow[J].Annals Biomed Engineering,2002,30:315-332.
  • 8Takagi J,Springer T A.Integrin activation and structural rearrangement[J].Immunol Rev,2002,186:141-163.
  • 9Pouyani T,Seed B.PSGL-1 recognition of P-selectin is controlled tyrosine sulfation consensus at the PSGL-1 amino terminus[J].Cell,1995,83:333-343.
  • 10Bienvenu J G,Tanguary J F,Theoret J F,et al.Recombinant soluble P-selectin glycoprotein ligand--Ig reduces restenosis through inhibition of platelet-neutrophil adhesion after double angioplasty in swine[J].Circulation,2001,103:1128-1134.

二级参考文献29

  • 1周同,李晓,吴佩,张东华,张明钧,陈楠,董德长.Effect of anti-P-selectin monoclonal antibody on renal ischemia/reperfusion injury in rats[J].Chinese Medical Journal,2000(9):22-25. 被引量:8
  • 2杜威世,王双,孙志伟,俞炜源.全合成人源性噬菌体抗体库的构建[J].军事医学科学院院刊,2006,30(4):319-322. 被引量:4
  • 3Lee CV,Liang WC,Dennis MS,et al.High-affinity human antibodies from phage-displayed synthetic Fab libraries with a single framework scaffold.J Mol Biol,2004,340(5):1073-1093.
  • 4Knappik A,Ge L,Honegger A,et al.Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides.J Mol Biol,2000,2960)57-86.
  • 5Mather JP.Engineered antibody therapeutics.Adv Drug Deliv Revi,2006,58(5/6):631-632.
  • 6Pascual V,Farkas L,Banchereau J.Systemic lupus erythematosns:all roads lead to type Ⅰ interferons.Curr Opin Immunol,2006,18(6):676-682.
  • 7Roanblom L.Aim GV.An etiopathogenic role for the type Ⅰ IFN system in SLE.Trends immunol,2001,22(8):427-431.
  • 8JBanchereau J,Pascual V.Type I interferon in systemic lupus erythematosus and other autoimmune diseases.Immunity,2006,25(3):383-392.
  • 9Ronnblom L,Alm GV.Systemic lupus erythematosus and the type Ⅰ interferon system.Arthritis Res Ther,2003,5(2):68-75.
  • 10Chantharapai A,Lal J,Huang X,et al.Characterization and humanization of a monoclonal antibody that neutralizes human leukocyte interferon:a candidate therapeutic for IDDM and SLE.Cytokine,2001,15(5):250-260.

共引文献27

同被引文献27

  • 1杜威世,王双,孙志伟,俞炜源.全合成人源性噬菌体抗体库的构建[J].军事医学科学院院刊,2006,30(4):319-322. 被引量:4
  • 2Prcnzel N, Fischer O M, Streit S, et al. The epidermal growth factor receptor family as a central element for cellu-lar signal transduction and diversification[J]. Endoer Relat Cancer, 2001,8:11-31.
  • 3Wosikowski K, Silverman J A, Bishop P, et al. Reduced growth rate accompanied by aberrant epidermal growth factor signaling in drug resistant human breast cancer cells[J]. Bio- chim Biophys Acta, 2000,1497:215-226.
  • 4Arteaga C L. The epidermal growth factor receptor: from mu- tant oneogene in nonhuman cancers to therapeutic target in human neoplasia[J]. J Clin Oncol, 2001,19:32-40.
  • 5Moon C, Chae Y K, Lee J. Targeting epidermal growth factor receptor in head and neck cancer: lessons learned from cetux- imab[J]. Exp Biol Med, 2010,235:907-920.
  • 6Garrett T P J, McKern N M, Lou M, et al. Crystal structure of a truncated epidermal growth factor receptor extraceilular domain bound to transforming growth factor α[J]. Cell, 2002, 110: 763-773.
  • 7Burgess A W, Cho H S, Eigenbrot C, et al. An open- and-shut case? Recent insights into the activation of EGF/ ErbB receptors[J]. Mol Cell, 2003,12:541-552.
  • 8Goldstein N I, Prewett M, Zuklys K, et al.B iological efficacy of a chimeric antibody to the epidermal growth factor recep- tor in a human tumor xenograft model[J].C fin Cancer Res, 1995,1:1311-1318.
  • 9Li S Q, Schmitz K R, Jeffrey P D, et al. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab [J].Cancer Cell, 2005,7:301-311.
  • 10Ullrich A, Coussens L, Hayflick J S, et al. Human epidermal- growth factor receptor cDNA sequence and aberrant expression- of the amplified gene in A341 epidermoid carcinomacells[J]. Nature, 1984,309(5967):418-425.

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部